Old Web
English
Sign In
Acemap
>
authorDetail
>
Emily Petito
Emily Petito
Johns Hopkins University School of Medicine
Pathology
Medicine
Veliparib
Circulating tumor cell
PARP inhibitor
3
Papers
4
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
2016
Journal of Clinical Oncology
Kim A. Reiss
Joseph M. Herman
Marianna Zahurak
Anthony Fyles
Michael Milosevic
Angela Scardina
Caitlin Joffe
Emily Petito
Amy Hacker-Prietz
Alice P. Chen
Sarah M. Temkin
Naomi Horiba
Robert J. Kinders
Lihua Wang
Lee-Anne Stayner
Nilofer Saba Azad
Show All
Source
Cite
Save
Citations (0)
A phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.
2011
Journal of Clinical Oncology
Shabina R. Ahmed
David Cosgrove
Douglas W. Ball
Ross C. Donehower
Barry D. Nelkin
Emily Petito
Melinda Downs
Helen X. Chen
A Doyle
Angela Scardina
Michael A. Carducci
Nilofer Saba Azad
Show All
Source
Cite
Save
Citations (1)
1